ChemoMetec · DK0060055861 · CHEMM | XCSE | Prime AI Terminal

CUSIP

K18309102

SEDOL

B28FRK9

CIK

N/A

chemometec.com

LEI: 213800533NBKECGONO68

New: Infographics X-Lab

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

ChemoMetec

Click to initiate

ENTERPRISE

6.003,27 S&P · 18,58 Vola-Index · 104.583,51 BTC · 1,13957 EURUSD

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Wed, 07.05.2025

Trading statement for Q3 2024/25 (1 January - 31 March 2025)

Research & Analysis

Mon, 10.02.2025

ANNOUNCEMENT NO. 288

Research & Analysis

Wed, 05.02.2025

ANNOUNCEMENT NO. 287

5 February 2025

Research & Analysis

Fri, 10.01.2025

ANNOUNCEMENT NO. 286

Research & Analysis

Tue, 03.12.2024

ANNOUNCEMENT NO. 285

Research & Analysis

Fri, 08.11.2024

ANNOUNCEMENT NO. 283

Research & Analysis

Thu, 07.11.2024

Trading statement for Q1 2024/25 (1 July - 30 September 2024)

Research & Analysis

Tue, 22.10.2024

ANNOUNCEMENT NO. 281

Research & Analysis

Wed, 16.10.2024

ANNOUNCEMENT NO. 280

Research & Analysis

Wed, 16.10.2024

ANNOUNCEMENT NO. 279

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

SMART * AD

P R O D U C T S U G G E S T I O N S

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

ChemoMetec A/S

Newsletter

ChemoMetec A/S

Continued growth in revenue and operating profit

Notification of managers' transactions

Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings

Upgrade of revenue and operating profit guidance

Upgrade of revenue and operating profit guidance

Notification of managers’ transactions

Growth in revenue and operating profit

Closing of acquisition of Ovizio Imaging Systems SA

Acquisition of Ovizio Imaging Systems SA

Upgrade of revenue and operating profit guidance

Newsletter